Clinical Trial Update: SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)

View source ↗

Summary

The completed trial conducted by Dana-Farber Cancer Institute evaluated SNP-based genetic markers for predicting oral mucositis risk in patients undergoing hema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Status: COMPLETED